Novo Nordisk raises guidance|Recovery or pipeline doubt?

A Good Quarter, A Falling Stock

Novo Nordisk just delivered the kind of quarter that normally rescues a battered stock. Adjusted sales rose 7% and adjusted operating profit 11%, while management narrowed its expected 2026 decline from 4–12% to 0–6%. Yet the U.S.-listed shares initially fell about 6%.

The Market’s New Question

That reaction says the market is no longer asking whether Novo can sell GLP-1 drugs. It is asking whether the company can still control the next phase of the market.

The Rebound Case Was Conditional

The pre-earnings case for a rebound was straightforward. Oral Wegovy had passed three million prescriptions, its first-mover advantage over Eli Lilly’s Foundayo looked meaningful, and Novo traded at a valuation far below its historical average. But that case was always conditional on three things: sustained prescription growth, manageable pricing pressure, and evidence that the pipeline could replace today’s blockbusters.

All Three Assumptions Weakened

The new results weakened all three assumptions. Wegovy pill sales reached 3.22 billion Danish kroner, but analysts expected 3.3 billion. That is a small miss, yet it mattered because the pill was supposed to be Novo’s clearest proof of renewed momentum. CagriSema, the next-generation candidate meant to challenge Lilly, matched tirzepatide on weight loss in a diabetes trial but failed to beat it on blood-sugar control. In other words, it showed no decisive advantage. Novo also recorded 6.3 billion kroner of noncash pipeline impairments, while its ZEUS cardiovascular trial failed to meet its primary endpoint.

Volume Growth Meets Price Pressure

The direct business mechanism is becoming clearer. Novo can still grow volume, but it is having to negotiate harder over price. The Wegovy pill is priced between $149 and $299 per month for self-paying U.S. customers, and more than 90% of its prescriptions initially came from that segment. That helps explain why the pill can add patients without immediately producing the sales scale investors want. Management argues that lower prices can unlock volume while preserving profitability. Investors are waiting to see whether that balance actually holds.

Evidence the Story Is Not Broken

There is real evidence against a permanently broken story. Novo says the pill has surpassed five million prescriptions, with weekly U.S. prescriptions above 265,000 by mid-July. Around 80% of pill users had not previously taken a GLP-1, suggesting the product may be expanding the market rather than merely cannibalizing injectable Wegovy. International launches in the United Kingdom, the United Arab Emirates and Germany could extend that growth. A BMO analyst also suggested that temporary wholesaler inventory effects may have contributed to the quarterly miss.

Lilly Is Raising the Bar

But Lilly is changing the comparison. Mounjaro sales rose 91% to nearly $10 billion, Zepbound generated another $4.9 billion, and Lilly said roughly three out of every four new injectable GLP-1 starts were going to its medicines. Even Foundayo, Lilly’s underwhelming new pill, was showing prescriptions roughly doubling month to month. Novo’s oral head start is therefore valuable, but it is not the same as having a durable moat.

The Bet After Wegovy

For holders, the important change is that NVO is no longer simply a bet on the obesity market. It is a bet on Novo’s ability to convert pill demand into profitable, scalable growth while defending share against Lilly and rebuilding a credible pipeline. For watchers, a low valuation and improved guidance are not enough by themselves. The more useful checkpoints are oral Wegovy prescriptions, realized pricing, margins, U.S. share, supply outside America, and whether CagriSema or another candidate can offer something better than parity. The next pipeline evidence includes further CagriSema developments and cardiovascular studies expected into 2027.

Resilient Today, Unproven Tomorrow

The remaining uncertainty is substantial. We do not yet know whether self-pay pill demand will translate into durable, reimbursed revenue, whether Novo can expand supply without constraining access, or whether its next medicines can regain pricing power. The better guidance proves that the existing business is more resilient than feared. It does not yet prove that Novo has solved the problem that caused the stock to fall: what comes after Wegovy and Ozempic.